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Malaria Outbreak in
Troops Returning
from French Guiana 
To the Editor: In January 2005,
the chief surgeon in a squadron of
French policemen reported a cluster
of Plasmodium vivax malaria attacks
in troops returning from a 108-day
operation in French Guiana. We con-
ducted a retrospective cohort study to
describe the malaria attacks and deter-
mine factors related to them.
A self-administered questionnaire
was drawn up, with questions con-
cerning operations in French Guiana
(dates, locations) and preventive
measures implemented against malar-
ia. A malaria case was defined by the
association of clinical signs and
Plasmodium parasites in blood smears
or quantitative buffy coat tests (per
definition of military epidemiologic
surveillance).
The 40-person mission in French
Guiana (Operation Anaconda) took
place from July 26, 2004, to
November 6, 2004 (108 days of expo-
sure). This mission against clandestine
gold panning was conducted in a deep-
forest environment where the troops
were temporarily housed in villages of
Brazilian gold panners. Occasionally,
they washed themselves late in the
evening in stagnant water near the
river and patrolled outside during
maximum biting periods. All troops
received a chemoprophylaxis (doxy-
cycline 100 mg daily) during the mis-
sion and for 4 weeks afterward.
From July 2004 through January
2005, 10 persons had >1 malaria
attacks (attack rate 25%) for a total of
18 malaria attacks (incidence 13/100
person-months of exposure). P. vivax
was isolated for 17 attacks and P. fal-
ciparum for 1 attack (Figure). Five
patients had 1 malaria attack, and 4
patients had up to 3 relapses. Six
patients had a malaria attack while
receiving doxycycline.
Regarding chemoprophylaxis com-
pliance, 34%  reported missing <1
dose per week and 32% were fully
compliant. The troops did not have
permethrin-impregnated battlefield
uniforms as do soldiers in the French
Army. They had to impregnate their
own uniforms with permethrin. Only
37% said they always wore clothing
that fully covered them during the
mission, and 86% reported having fre-
quently used a repellent. All reported
having slept under mosquito nets. No
association was found between malar-
ia attacks and regular chemoprophy-
laxis intake or use of repellents. Only
1 operation in French Guiana was
associated with the risk of experienc-
ing malaria attacks: 39% of troops
located in Sikini had at least 1 malar-
ia attack versus 7% of troops in other
areas (relative risk: 5.9 [95% confi-
dence interval 0.8–41.7]).
The incidence rate for this study
was 10 times higher than the maxi-
mum incidence rate observed for
French troops deployed in Côte
d’Ivoire (1.3/100 troop-months in
2004). During an earlier Operation
Anaconda, 37 of 62 persons deployed
near the Sikini area had >1 malaria
attacks (attack rate 61%). Of these, 30
had >1 attacks caused by P. vivax;
occasionally an attack was associated
with P. falciparum (1).
Our results suggest that the Sikini
area was the high-risk area for malar-
ia transmission (although the large
confidence interval reflects a lack of
power in our analysis). The operation
dates (15–28 September) are compat-
ible with the duration of the first cases
of malaria occurrence.
French Guiana is the only French
territory, except for Mayotte, where
malaria is endemic, with nearly 5,000
cases per year, occurring mainly
along the rivers bordering Suriname
and Brazil (2). The highest frequen-
cies of malaria appear during the dry
season (September to December) in
French Guiana (3), but no seasonality
was described near the Brazilian bor-
der (4).
The Sikini area is located near the
Oyapock River (Brazilian border).
The mean annual incidence in Amer-
indians there is 48.6%, mainly due to
P. falciparum (incidence 24.8%) and
P. vivax (incidence 25.9%) (2).
P. vivax malaria incidence has
increased in the Oyapock region,
from 30% in 1987 to 50% in
2000–2004 (2,4–7). French troops
were deployed in an area where para-
site circulation was high. Troops had
Figure. Epidemic curve of malaria attacks. Pv, Plasmodium vivax; Pf, P. falciparum; 1,
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contacts with clandestine gold pan-
ners, mainly Brazilian illegal resi-
dents. This population, in which
malaria incidence is almost impossi-
ble to evaluate, comes from Amapa
State, where the incidence of malaria
is increasing (5). In 2003, 60.9% of
patients with malaria cases at
Cayenne Hospital had a Brazilian
name compared with 35.4% in 2000
(6). Also, the gold panners diverted
the river and built basins where vec-
tors could easily multiply (7).
Initial malaria attacks were treated
with chloroquine or quinine. Five
patients experienced >1 relapses
(maximum 3 relapses). The relapses
were treated with 50-mg daily doses
of primaquine for 4 patients and by
chloroquine for the fifth patient. Two
patients had relapses after receiving
primaquine. Primaquine resistance
information was not available.
However, resistance to primaquine
has emerged in P. vivax strains (8).
We recommended that pre-impreg-
nated battlefield uniforms be available
for French policemen and chemopro-
phylaxis adherence be reinforced by
directly observed intake by superviso-
ry staff. Relapses of P. vivax malaria
are a major therapeutic problem, par-
ticularly after primaquine therapy.
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Plasmodium vivax
Malaria Relapses
after Primaquine
Prophylaxis 
To the Editor: Standard treatment
of patients with Plasmodium vivax
malaria includes chloroquine, fol-
lowed by primaquine terminal pro-
phylaxis. Reports of true primaquine
failure and subsequent P. vivax
relapse are unusual; most suspected
cases can be ascribed to poor patient
adherence, recrudescence of a chloro-
quine-resistant strain, or P. vivax rein-
fection. We report a case of P. vivax
malaria relapse after therapy with qui-
nine, doxycycline, and primaquine,
and again after treatment with chloro-
quine and primaquine. P.  vivax
relapses after primaquine treatment
are exceedingly rare in travelers to
South America and are a serious ther-
apeutic challenge. Our patient was
subsequently treated with weekly, sin-
gle-dose chloroquine without recur-
rence of symptoms.
A 77-year-old man had fever and
chills 2 weeks after returning from
Brazil. These symptoms were accom-
panied by sweating, fatigue, and a
mild, productive cough. Review of
systems was notable for dark, con-
centrated urine and a 10-lb weight
loss. The patient’s 25-day journey
included Salvador, Manaus, and a 2-
day stay in the Amazon River basin.
He did not take malaria prophylaxis
during his trip.
On physical examination, the
patient was afebrile with blood pres-
sure of 90/53 mm Hg. Cardio-
vascular, pulmonary, and abdominal
examination results were unremark-
able. Several petechiae were noted on
both lower extremities. Laboratory
tests showed the following: leukocyte
count 6,300 cells/µL, hemoglobin
level 13.7 g/dL, platelet count 40,000
cells/µL, serum creatinine level 1.2
mg/dL, serum alanine aminotrans-
ferase level 63 IU/L, and serum
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